Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer.
Department of Urology, Philipps-University Medical School, Marburg, Germany. ajschrader@gmx.de
Andres J
AJ
Schrader
Zoltan
Z
Varga
Susanne
S
Pfoertner
Ulrike
U
Goelden
Jan
J
Buer
Rainer
R
Hofmann
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D013792:Thalidomide